Investor Update

Basel, 20 September 2013

First HER2 targeted Antibody Drug Conjugate “Kadcyla®”, an Anti-Cancer Agent Approved for HER2-positive Inoperable or Recurrent Breast Cancer

Dear Investor,

Please find attached a press release by Chugai:

Do not hesitate to contact us for any further questions.